Beta Bionics (BBNX) leads innovation in the diabetes treatment market with its groundbreaking iLet Bionic Pancreas technology ...

Beta Bionics announced today that it went public after pricing a significantly upsized initial public offering (IPO).

Underwriters have a 30-day option to buy an additional 1.8 million shares. Beta Bionics also agreed to sell 1 million shares ...

Beta Bionics today filed a prospectus outlining its aim to bring in $114.4 million in its initial public offering (IPO).

Beta Bionics has begun life as a public company with a $204m initial public offering (IPO), significantly higher than its ...

Beta Bionics (BBNX), a developer of insulin delivery devices, has set terms for an upsized $165M initial public offering. In a recent SEC filing, the company said it was now looking to offer 10M ...

The company estimates that its install base surpassed 15,000 by the end of last year, leading to sales of more than $20 ...

Beta Bionics, Inc. (BBNX) is planning to raise $112 million in an initial public offering on Thursday, January 30th, IPO Scoop reports. The company will be issuing 7,500,000 shares at $14.00-$16.00 ...

Based in Irvine, Calif., Beta Bionics' (BBNX) lead product is an insulin delivery device called iLet Bionic Pancreas that utilizes adaptive closed-loop algorithms to autonomously determine insulin ...

The iLet links an automated pump with an adaptive, closed-loop dosing algorithm, which calculates a user’s background insulin needs without them having to count their carbohydrates. Instead ...

Irvine-based medical device company Beta Bionics Inc. on Jan. 6 filed an S-1 with the Securities and Exchange Commission to list on the Nasdaq under the symbol “BBNX.” ...